In Thursday’s Wall Street session, Halozyme Therapeutics Inc (NASDAQ:HALO) shares traded at $67.73, down -3.44% from the previous session.
HALO stock price is now 10.57% away from the 50-day moving average and 20.11% away from the 200-day moving average. The market capitalization of the company currently stands at $8.35B.
With the price target enhanced from $58 to $62, Wells Fargo Downgraded its rating from Overweight to Equal Weight for Halozyme Therapeutics Inc (NASDAQ: HALO). On September 19, 2024, JP Morgan Downgraded its previous ‘Overweight’ rating to ‘Neutral’ on the stock increasing its target price from $52 to quote $57, while ‘Piper Sandler’ rates the stock as ‘Neutral’
In other news, Henderson Jeffrey William, Director sold 4,497 shares of the company’s stock on Apr 28 ’25. The stock was sold for $271,467 at an average price of $60.37. Upon completion of the transaction, the Director now directly owns 28,611 shares in the company, valued at $1.94 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 01 ’25, Director Henderson Jeffrey William sold 503 shares of the business’s stock. A total of $32,217 was realized by selling the stock at an average price of $64.05. This leaves the insider owning 33,108 shares of the company worth $2.24 million. A total of 1.06% of the company’s stock is owned by insiders.
During the past 12 months, Halozyme Therapeutics Inc has had a low of $41.28 and a high of $70.50. As of last week, the company has a debt-to-equity ratio of 3.13, a current ratio of 8.39, and a quick ratio of 7.30.
The net profit margin was 44.76% and return on equity was 147.06% for HALO. The company reported revenue of $264.86 million for the quarter, compared to $195.88 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 35.22 percent.
